Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Shukui Qin
Observed name:
S. Qin
Institutions:
Nanjing University of Chinese Medicine,
China Pharmaceutical University,
Nanjing General Hospital of Nanjing Military Command,
81th Hospital of PLA,
Nanjing Medical University
Observed institutions:
Nanjing University of Chinese Medicine,
China Pharmaceutical University,
Nanjing General Hospital of Nanjing Military Command,
81th Hospital of PLA,
Nanjing Medical University
ORCID:
0000-0001-9772-132X
Observed ORCID:
0000-0001-9772-132X
OpenAlex ID:
A5101696576
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
2024
·
George Lau
, Shuntaro Obi
, et al.
·
Hepatology International
·
103
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
2025
·
Shukui Qin
, Shanzhi Gu
, et al.
·
The Lancet Oncology
·
50
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses.
2025
·
Masatoshi Kudo
, Thomas Yau
, et al.
·
Journal of Clinical Oncology
·
15
Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT
2024
·
Richard S. Finn
, Shukui Qin
, et al.
·
Liver Cancer
·
13
LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma.
2025
·
Richard S. Finn
, Masatoshi Kudo
, et al.
·
Journal of Clinical Oncology
·
8
Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition)
2025
·
Zheng Wang
, Huichuan Sun
, et al.
·
HepatoBiliary Surgery and Nutrition
·
6
GS-005 Outcomes by liver function in patients with unresectable hepatocellular carcinoma treated with nivolumab plus ipilimumab vs lenvatinib or sorafenib in the CheckMate 9DWtrial
2025
·
Bruno Sangro
, Masatoshi Kudo
, et al.
·
Journal of Hepatology
·
5
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study
2025
·
Feng Bi
, Shukui Qin
, et al.
·
European journal of medical research
·
2
PDF
135P Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in advanced biliary tract cancer (aBTC)
2024
·
D-Y. Oh
, A.R. He
, et al.
·
Annals of Oncology
PDF
Data from Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
2024
·
Richard S. Finn
, Masatoshi Kudo
, et al.
Supplementary Data from Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
2024
·
Richard S. Finn
, Masatoshi Kudo
, et al.
Supplementary Excel_nCounter PanCancer Human Pathways Panel Gene List from Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
2024
·
Richard S. Finn
, Masatoshi Kudo
, et al.
136MO Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC): East Asia subgroup of FIGHT final analysis
2023
·
Y-K. Kang
, S. Qin
, et al.
·
Annals of Oncology
PDF
Investigation on popular science of malignant tumor and attitude and behavior about prevention and control among the young officers and soldiers.
2016
·
Huang Yong
, Shukui Qin
, et al.
·
Chinese Clinical Oncology
Progress in drug treatment for advanced pancreatic carcinoma
2012
·
Shukui Qin
·
Zhongguo xin yao zazhi
Treatment strategies of primary hepatocellular carcinoma with portal vein tumor thrombus.
2010
·
Jun Qian
, Shukui Qin
·
肿瘤研究与临床
Research of chronic psychological stress promoting tumor angiogenesis of mice
2009
·
Shukui Qin
·
Zhonghua zhongliu fangzhi zazhi
Progress in research of multi-kinase inhibitors for treatment of hepatocellular carcinoma
2009
·
Shukui Qin
·
Zhongguo xin yao zazhi
A retrospective analysis of high-dose opioids analgesics management for cancer pain
2009
·
Yingxia Chen
, Shukui Qin
, et al.
·
Chinese Clinical Oncology
Pharmacokinetics of hydroxycamptothecine injection in cancer patients
2007
·
Shukui Qin
·
Chinese Journal of Clinical Pharmacy
Methodology study of arsenic concentration in the plasma sample measured by hydride generation atomic fluorescence spectrometry
2005
·
Qin Shu-ku
, Shukui Qin
·
Chinese Clinical Oncology
Show more works
View as search
Works count:
21
Citation count:
202
H-index:
6
I10-index:
4
Year
Topic
Type